Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegenzileukin - Sanofi

Next Previous
Drug Profile

Pegenzileukin - Sanofi

Alternative Names: IBI-127; Non alpha IL-2 - Sanofi; Non alpha synthorin of IL-2 - Sanofi; SAR-444245; THOR-707

Latest Information Update: 29 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Synthorx
  • Developer Merck Sharp & Dohme; Sanofi
  • Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins; Recombinant proteins
  • Mechanism of Action Interleukin 2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II B-cell lymphoma; Gastrointestinal cancer; Hodgkin's disease; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Squamous cell cancer
  • Discontinued Solid tumours

Most Recent Events

  • 02 Dec 2025 Sanofi terminates a phase I/II HAMMER trial in Solid tumours (Combination therapy, Metastatic disease, Late-stage disease, Monotherapy, Second-line therapy or greater) in USA, Argentina, Australia, Chile, Singapore and Spain, due to sponsor decision (IV) (NCT04009681)
  • 31 Dec 2024 Discontinued - Phase-I/II for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Singapore, USA, Australia (IV)
  • 31 Dec 2024 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Singapore, USA, Australia (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top